COSTEM 2024
  • Acute leukemia
  • Artificial Intelligence (AI)

  • Bi-specific antibodies

  • CMV infection

  • CAR T-cell therapy and cellular therapy

  • Cord blood transplantation

  • Donor lymphocyte infusion

  • Drug conjugated antibodies

  • Genome editing and gene therapy

  • GvHD prevention and treatment

  • Haploidentical stem cell transplantation

  • Hodgkin and Non-Hodgkin lymphoma

  • Infectious complications

  • Mesenchymal stem cell

  • Multiple myeloma

  • Myeloproliferative neoplasm

  • Myelodysplastic syndrome

  • NK Cell therapy

  • Pediatric indications for transplantation

  • Relapse prevention

  • Stem cell transplantation

  • TCR engendering based immunotherapy

  • Toxicity post transplantation (VOD, TMA, etc.)

  • Transplant for severe aplastic anemia and haemoglobinopathies

  • Virus specific T Cell therapy